Skip to main content

Pancreatic Cancer Clinical Trials

Review the pancreatic cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 291

Comparing two Chemotherapy Regimens (NALIRIFOX and mGAP) in the Treatment of Locally Advanced, Unresectable, and Metastatic Pancreatic Adenocarcinoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
FOLFIRINOX Chemotherapy Before Surgery in Treating Patients with Non-Metastatic Pancreatic Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
BMS-986504 and Chemotherapy for the Treatment of Resectable, Locally Advanced, Unresectable, or Metastatic, MTAP-Deleted Pancreatic Ducal Adenocarcinoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Odetiglucan and Mitazalimab as Maintenance Therapy in Patients with Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Sequential Cytoreductive Interventions for the Treatment of Patients with Metastatic Digestive System Adenocarcinoma with Undetectable ctDNA
Status: Active
Location: Yale University, New Haven, Connecticut
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Immunotherapy (EGFR FPBMC) for the Treatment of Locally Advanced, Metastatic, or Unresectable Pancreatic Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
AGEN2373 in Combination with GVAX or mKRASvax for the Treatment of Patients with Stage I or II Resectable Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
iExosomes in Combination with Ipilimumab for the Treatment of Patients with Metastatic Pancreas Cancer with KrasG12D Mutation
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Pegcetacoplan in Combination with Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Gemcitabine and Nab-Paclitaxel With or Without ONT01 for the Treatment of Unresectable/Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status: Active
Location: 2 locations
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York